Comparative Safety of Janus Kinase inhibitors vs. Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

doi:10.1016/j.cgh.2025.06.041

Comparative Safety of Janus Kinase inhibitors vs. Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

2025-07-28

0

PRE

AI

Ashwin N. Ananthakrishnan

DOI：10.1016/j.cgh.2025.06.041

Original

Original request for help

Save

Abstract

En 中文

We conducted a retrospective cohort study comparing the safety of Janus kinase (JAK) inhibitors vs. tumor necrosis factor-α (TNF) antagonists in patients with inflammatory bowel diseases (IBD).

Keywords:

JAK inhibitors

TNF antagonists

inflammatory bowel diseases

retrospective cohort study

drug safety

Comparative Safety of Janus Kinase inhibitors vs. Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

Abstract

Journal

Organization